🔴 BioNTech is trading 6.6% down in pre-market — no clear overnight catalyst identified

BioNTech is trading at $89.50, down 6.62%; sources reviewed surfaced no clear overnight catalyst.

• The latest BioNTech headlines found were dated October 9, covering analyst coverage and an NIH cancer-vaccine initiative—not a new October 13 company event.
• MarketWatch lists no October 13 announcement; its cited cancer-vaccine setback coverage dates to August.
• The supplied market picture is mixed and does not establish a broad-market cause for the drop.